Dodging, Data and Delays: FDA, CYBN, EPRX & CLRB
Last week, the biotech market was in a funk due to the uncertainty around RFK Jr.’s selection to lead the Department of Health and…
Coverage
Blog
Latest research notes and coverage from the editorial archive.
Protara (TARA) Closing the Gap & Sunshine, Psychedelics and Cybin (CYBN)
Protara Therapeutics (Nasdaq: TARA) is expected to deliver interim data for TARA-002 from their ADVANCE-2 trial before year-end (likely at the Society of Urological…
Epilepsy’s Hot, Can OVID “Seize” The Opportunity?
Ovid Therapeutics (Nasdaq: OVID) has recently piqued our interest. The company’s stock plunged earlier this year after its partner, Takeda Pharmaceuticals (NYSE: TAK), announced…
Speculating on Bright Minds (DRUG) & Delcath (DCTH) Exceeds Expectations
Epic Short Squeeze? Last week, the biggest news in biotech was Lundbeck’s $2.6b acquisition of Longboard Pharmaceuticals (Nasdaq: LBPH). However, Longboard’s success was arguably…
Sanofi Invests in NLRP3 (VTYX) & FDA Countdown is on (ENTX)
Toe In The Water Last month, Ventyx Biosciences (Nasdaq: VTYX) announced that it had received a $27mm equity investment ($3.82/share) from Sanofi (NYSE: SNY)…
An Early New Year’s “Rezolution”; Don’t Miss Rezolute (RZLT) Again
Fighting Laziness It can be difficult to objectively analyze a stock after it has already made a big move. Often, we assume that “we…
Soleno (SLNO) Takes Center Stage, Delcath (DCTH) & Data, and Modular (MODD) “Almost” There…
Must Watch Biotech Theatre Over our past few notes, we have written about the importance of companies managing investor expectations. Within our universe, no…
Xenon (XENE), Delcath (DCTH), Protara (TARA) and Other Q2 Musings
Pipeline in a Drug & A Real Pipeline Xenon Pharmaceuticals (Nasdaq: XENE) is in the early innings of evolving from a pipeline in a…
Managing Expectations: Cellectar (CLRB) & Delcath (DCTH)
Cellectar Biosciences (Nasdaq: CLRB) was a topical name last week, announcing a financing, additional data from their Waldenstrom’s macroglobulinemia (WM) pivotal study, and hosting…
Cellectar’s (CLRB) Next Big Milestone, Can Satellos (MSCL) Play Well With Sarepta (SRPT)? and Ventyx (VTYX) Reeling
Let The Stock Breathe Cellectar Biosciences (Nasdaq: CLRB) stock has recently made a roundtrip back to its January pre-CLOVER WaM pivotal data release price. …